Answers are grounded in this paper and cite their sources.
NexP™ is a proprietary carrier platform engineered from human alpha-1 antitrypsin (A1AT) to extend the systemic exposure of therapeutic proteins while retaining biological activity. The NexP™ scaffold incorporates an additional N-linked glycosylation site and a mutation in the reactive center loop designed to reduce its intrinsic protease inhibitory activity. Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological performance, safety profile, and developability of the NexP™ platform. ALT-P1, a long-acting hGH candidate, containing NexP™ at its C-terminus of hGH, was produced in mammalian cells and purified by a series of column chromatography steps. The purified protein was characterized Human growth hormone (hGH) was selected as a model therapeutic protein to evaluate the pharmacological properties, nonclinical safety, and developability of this platform. ALT-P1, an hGH fusion protein containing NexP™ at its C-terminus, was produced in mammalian cells and purified using chromatographic methods. ALT-P1 was characterized by physicochemical analyses, including SDS-PAGE, isoelectric focusing, size-exclusion chromatography, N-linked glycan profiling, and circular dichroism (CD) spectroscopy. Binding affinity for the human growth hormone receptor and in vitro activity were further assessed by receptor-binding, MTS-based cell proliferation and luciferase reporter assays. Pharmacokinetic, pharmacodynamic, and toxicological profiles were evaluated in Sprague-Dawley rats and cynomolgus monkeys. Systemic exposure to ALT-P1 increased with increasing subcutaneous doses in rats, and pharmacokinetic studies demonstrated sustained systemic exposure in both species. ALT-P1 increased serum insulin-like growth factor I (IGF-1) levels in cynomolgus monkeys and promoted body weight gain and tibial growth in hypophysectomized rats. In a 26 week repeated-dose toxicity study in cynomolgus monkeys, ALT-P1 was generally well tolerated, with a no-observed-adverse-effect level (NOAEL) of 20 mg/kg, the highest dose tested. A GMP-manufactured clinical batch maintained its quality attributes and biological potency during long-term storage. Collectively, these findings support the further development of ALT-P1 as a long-acting hGH candidate and suggest the potential applicability of NexP™ as a half-life-extension platform for other biologic therapeutics.
No takes yet. Share an insight, caveat, or question.
Ko et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: